Sono-Tek outlines facility expansion to lift manufacturing capacity to $33M-$36M, with plan toward $44M-$45M

Earnings Call Insights: Sono-Tek Corporation (SOTK) Q2 fiscal 2027

Management view

• “The first half of fiscal 2027 represented solid progress for Sono-Tek with revenue growth, meaningful gross margin expansion and improved operating profitability.” (Executive Chairman Christopher Coccio)

• “Now for the first half, revenue increased 6% to approximately $10.9 million. Gross margin expanded to 55% compared to 51% in the prior year period. Operating income increased 41% to approximately $1.28 million and net income increased 22% to approximately $1.1 million.” (Executive Chairman Coccio)

• “The medical market sales increased 289% to approximately $7.1 million.” (Executive Chairman Coccio)

• “We recently announced 3 orders, totaling approximately $7.2 million, which cover 10 production scale systems and represent the largest aggregate customer order in Sono-Tek's history.” (Executive Chairman Coccio)

• “Together with the more than $3.6 million medical diagnostic production line order announced in August, these programs alone now represent more than $10.79 million of backlog, with the majority currently expected to be delivered in fiscal year 2028.” (Executive Chairman Coccio)

• “We are reiterating our expectation for flat to modest revenue growth for this current fiscal 2027.” (President, CEO & Director R. Harshbarger)

• “For the second quarter ended August 31, 2026, total revenue was approximately $5.23 million compared with $5.16 million for the prior year period.” (Chief Financial Officer Stephen Bagley)

• “As of August 31, 2026, cash and marketable securities totaled approximately $17.7 million… and we continue to have no debt.” (CFO Bagley)

Outlook

• “We are reiterating our expectation for flat to modest revenue growth for this current fiscal 2027.” (CEO Harshbarger)

• “The 10 systems are currently expected to ship primarily during fiscal 2028.” (CEO Harshbarger)

• “Following quarter end, we received 3 additional orders totaling approximately $7.19 million.” (CFO Bagley)

• The prior-quarter transcript was not included in the materials provided, so changes versus last quarter’s guidance language could not be verified from transcripts.

Financial results

• “For the second quarter ended August 31, 2026, total revenue was approximately $5.23 million… Gross profit for the second quarter was approximately $2.8 million… Gross profit margin was approximately 53%… [and] our operating income for the second quarter decreased by 9%… to $382,000.” (CFO Bagley)

• “For the first half, gross profit increased 14% to approximately $6 million… gross profit margin expanded to 55%… [and] net income for the first half increased 22% to approximately $1.11 million.” (CFO Bagley)

• “Backlog at August 31 was approximately $9.5 million, representing a 23% increase from the end of the first quarter.” (CFO Bagley)

• “Gross margins can vary significantly from period to period… [and] the gross margin levels achieved during the first half of fiscal 2027 should not necessarily be viewed as indicative of margins expected in future periods.” (CFO Bagley)

Q&A

• Bill Nicklin, Bill Will Insights: asked whether integrated production-line wins create a “flywheel effect” and how that affects investment priorities; President Harshbarger: “we're really starting to put a much greater emphasis on expanding our systems integration capabilities… particularly through our forward deployed engineering team,” adding, “I would expect us to continue expanding their capabilities over the next year or 2.”

• Edward Jackson, Northland Capital Markets: asked about expanding medical balloon opportunities and adjacent device categories; CEO Harshbarger: “we are… the industry leader for coating drug-eluting balloons,” and “customers… now have a very high level of confidence coming to us with their next-gen medical device.”

• Jackson, Northland Capital Markets: asked what other new markets management is excited about; CEO Harshbarger: “the defense sector has a lot of applications,” “the microelectronics sector… has a lot of nice applications,” and “the concept… is… proving it… and then transitioning to high-volume production.”

• Jackson, Northland Capital Markets: asked about manufacturing capacity; CEO Harshbarger: “We are intending to start a major… expansion at the end of this current calendar year,” and “take our existing manufacturing footprint from… around $27 million capped, up to around $33 million to $36 million peak… [and]… take us up to around $44 million to $45 million in manufacturing capability.”

• Sam Dufault, Oak Ridge Financial: asked about CapEx for the mezzanine expansion; CEO Harshbarger: “the initial CapEx we had estimated at around $700,000,” and “retrofitting the next building… will also be somewhere in the area of about a $600,000 CapEx investment.”

• Dufault, Oak Ridge Financial: asked about gross margin drivers and sustainability; CEO Harshbarger: “repeat high ASP machine orders are kind of the best case scenario,” while adding, “the coming quarter may be not quite as attractive… [but] what's flowing into our backlog is… more of these high ASP, high volume production systems.”

• Gregory Weaver, Invicta Capital: asked about medical visibility and services; CEO Harshbarger: “the level of activity in our labs… is very high,” and on services, “we will start to see a reoccurring revenue stream… as these machines start to fall out of warranty.”

• Weaver, Invicta Capital: asked about operating leverage; CEO Harshbarger: “from that $22 million to, say, $40 million area… It's going to flow through,” while noting continued investment “in that forward-deployed engineering team area.”

• Jason Ursaner, Bumbershoot Holdings: asked about semiconductor/microelectronics scope and timing; CEO Harshbarger: “we're already attacking… 200-millimeter,” “making a shift towards larger 300-millimeter wafers,” and “for a really significant impact… we may be out, 1, 2 years, maybe even 3 years.”

Sentiment analysis

• Analysts were largely slightly positive and probing on scalability and durability, emphasizing visibility, margins, and capacity, including “visibility on your medical business continuing at these nice levels” (Gregory Weaver, Invicta Capital) and “commentary on margins going forward… if the current levels are sustainable” (Sam Dufault, Oak Ridge Financial).

• Management tone was slightly positive and expansion-oriented, leaning on confidence signals around integration and scale, including “now that we have proven the model is successful… we're going to be doubling down on that” (CEO Harshbarger) and “we are intending to start a major… expansion” (CEO Harshbarger).

• A comparison of tone versus the prior quarter could not be supported because the prior-quarter transcript was not provided.

Quarter-over-quarter comparison

• The previous-quarter transcript was not available in the provided materials, so quarter-over-quarter shifts in guidance language, strategy emphasis, and analyst focus could not be corroborated from transcripts.

Risks and concerns

• “Alternative energy in the first half reflected reduced demand associated with changes in government policy and spending.” (CEO Harshbarger)

• “Gross margins can vary significantly from period to period… based on… a specific system shipped, customer and geographic mix, distributor involvement, installation requirements and other factors.” (CFO Bagley)

• On near-term margin variability, management cautioned, “the coming quarter may be not quite as attractive because we don't have those same high ASP systems in them.” (CEO Harshbarger)

Final takeaway

Management emphasized a first-half performance mix-shift toward medical and higher-value production systems, highlighted record alternative-energy orders and a growing backlog weighted to fiscal 2028 deliveries, reiterated an expectation for flat to modest fiscal 2027 revenue growth, and outlined near-term and longer-range manufacturing capacity expansion plans while continuing to “double down” on systems integration and forward-deployed engineering to drive larger, repeat production-platform orders.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.